What is HC Wainwright's Estimate for Korro Bio Q1 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Research analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Korro Bio in a research report issued on Thursday, March 20th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($2.54) per share for the quarter, down from their previous forecast of ($2.45). HC Wainwright has a "Buy" rating and a $115.00 price objective on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio's Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, beating analysts' consensus estimates of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter.

Several other analysts have also issued reports on the company. Oppenheimer assumed coverage on Korro Bio in a report on Friday, January 10th. They set an "outperform" rating and a $155.00 price objective for the company. Royal Bank of Canada cut their price target on Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research note on Wednesday, March 19th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Korro Bio currently has a consensus rating of "Buy" and a consensus price target of $142.57.

Remove Ads

Korro Bio Trading Down 9.0 %

KRRO stock traded down $2.15 during midday trading on Monday, reaching $21.88. The company had a trading volume of 13,846 shares, compared to its average volume of 78,694. The company has a 50 day moving average of $29.60 and a two-hundred day moving average of $41.23. The company has a market capitalization of $205.39 million, a P/E ratio of -2.33 and a beta of 2.13. Korro Bio has a 1 year low of $18.50 and a 1 year high of $98.00.

Institutional Trading of Korro Bio

Institutional investors and hedge funds have recently modified their holdings of the company. AlphaQuest LLC raised its stake in shares of Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock valued at $83,000 after buying an additional 412 shares in the last quarter. Bank of New York Mellon Corp raised its position in Korro Bio by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company's stock worth $563,000 after purchasing an additional 435 shares in the last quarter. Bank of America Corp DE lifted its stake in Korro Bio by 9.0% during the fourth quarter. Bank of America Corp DE now owns 7,037 shares of the company's stock worth $268,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers boosted its holdings in Korro Bio by 7.8% during the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock valued at $366,000 after purchasing an additional 691 shares in the last quarter. Finally, Blair William & Co. IL grew its stake in shares of Korro Bio by 5.7% in the 4th quarter. Blair William & Co. IL now owns 12,895 shares of the company's stock valued at $491,000 after purchasing an additional 695 shares during the period. 13.18% of the stock is currently owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).